IP Library Granted Patent US 11,946,094
Granted Patent B2
US 11,946,094 · App. 16/214,658 · Granted Apr 2, 2024

Combination therapies and methods of use thereof

Inventors: Jin-Xiong She (Augusta, GA); Robert Schleifer (Sugar Hill, GA); Shuchun Li (Martinez, GA)
Assignee: Augusta University Research Institute, Inc.
C12Q1/025G01N33/5008G01N33/57496G01N2500/02G01N2500/10G01N2800/44G01N2800/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,946,094
App. No.
16/214,658
Granted
Apr 2, 2024
Kind
B2
Abstract

A method for identifying drug resistant genes and compositions containing agents that downregulate these genes in combination with a cancer therapeutic.

Claims (6)

1. A pharmaceutical composition comprising an effective amount of an inhibitor of a HDAC in combination with an effective amount of a siRNA that synergistically inhibits or reduces expression of a drug resistance gene, wherein the drug resistant gene is S100A11.

2. The pharmaceutical composition of claim 1 , further comprising a chemotherapeutic agent.

3. A method for inhibiting proliferation of solid tumor cells, comprising administering a composition comprising an effective amount of an inhibitor of a HDAC in combination with an effective amount of a siRNA that synergistically inhibits or reduces the expression of a drug resistance gene wherein the drug resistance gene is S100A11 and wherein reducing the expression of the drug resistance gene increases the effectiveness of the inhibitor.

4. The method of claim 3 , wherein the inhibitor is administered simultaneously with the siRNA.

5. The method of claim 3 , further comprising administering to the solid tumor cells a PD-1 antagonist in combination with the inhibitor.

6. The method of claim 3 , wherein the solid tumor cell is a lung cancer cell.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2019
From: SHE, JIN-XIONG; SCHLEIFER, ROBERT; LI, SHUCHUN
To: AUGUSTA UNIVERSITY
Reel/Frame 047948/0593 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2019
From: AUGUSTA UNIVERSITY
To: AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.
Reel/Frame 047949/0179 →
CONFIRMATORY LICENSE Recorded Dec 14, 2018
From: AUGUSTA UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 049014/0674 →
Continuity (3)
Provisional Application 62596888 · Dec 10, 2017
Provisional Application 62596889 · Dec 10, 2017
Related Publication 20190177765A1 · Jun 13, 2019